nach oben

Erschienen in:

01.04.2022 | Original Paper

A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways

verfasst von: Marzieh Shirin, Sajedeh Madadi, Noshad Peyravian, Zahra Pezeshkian, Leili Rejali, Masoumeh Hosseini, Afshin Moradi, Binazir Khanabadi, Ghazal Sherkat, Hamid Asadzadeh Aghdaei, Ehsan Nazemalhosseini-Mojarad

Erschienen in: Medical Oncology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Different molecular signaling pathways have been involved in the incidence and progression of CRC. We aimed to examine the correlation between eight candidate genes, including TFGβ, SMAD2, SMAD4, RhoA, EGFR, MAP2K1, MTA1, and LEF1 in the progression of colorectal cancer (CRC) and their association with clinicopathological variables and CRC patients prognosis. Immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR) analysis 2^−ΔΔct, were performed to assess the expression of eight genes in 64 and 122 patients with CRC, respectively and 20 normal samples were added for verification. We showed a positive correlation between SMAD2 and MAP2K1 (r = 0.337, P < 0.001), MAP2K1 and LEF1 (r = 0.187, P = 0.03), SMAD4 and RhoA (r = 0.214, P = 0.01) and as well, a negative correlation between SMAD2 and TGFβ (r = − 0.197, P = 0.02), and RhoA and LEF1 (r = − 0.180, P = 0.04) in tumor tissues. A decrease in RhoA mRNA expression was associated with the advanced TNM stage (P = 0.01), while the EGFR and SMAD2 mRNA expression upregulated in advanced stages (P = 0.03, P = 0.03), respectively. Also, an increase in EGFR and SMAD4 protein expression was significantly associated with the advanced TNM stage (P = 0.000) (P = .002), respectively. Perceiving the connections between canonical and non-canonical Transforming growth factor (TGF-β) signaling pathway along with the epidermal growth factor receptor (EGFR) and WNT cascades may trigger the development of novel approaches for CRC prediction.

Nur mit Berechtigung zugänglich

Koveitypour Z, Panahi F, Vakilian M, Peymani M, Seyed Forootan F, Nasr-Esfahani MH, et al. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019. https://doi.org/10.1186/s13578-019-0361-4.CrossRefPubMedPubMedCentral

Asadzadeh Aghdaei H, Pezeshkian Z, Abdollahpour-Alitappeh M, Nazemalhosseini Mojarad E, Zali MR. The role of angiogenesis in colorectal polyps and cancer, a review. Med Lab J. 2018;12(4):1–6.

Peyravian N, Larki P, Gharib E, Nazemalhosseini-Mojarad E, Anaraki F, Young C, et al. The application of gene expression profiling in predictions of occult lymph node metastasis in colorectal Cancer patients. Biomedicines. 2018;6(1):27.PubMedCentral

Pranteda A, Piastra V, Stramucci L, Fratantonio D, Bossi G. The p38 MAPK signaling activation in colorectal cancer upon therapeutic treatments. Int J Mol Sci. 2020;21:2773.PubMedCentral

Nie X, Liu H, Liu L, Wang Y-D, Chen W-D. Emerging roles of Wnt ligands in human colorectal cancer. Front Oncol. 2020;10:1341.PubMedPubMedCentral

Cheruku H, Mohamedali A, Cantor D, Tan SH, Nice E, Baker M. Transforming growth Factor-β, MAPK and Wnt signaling interactions in colorectal cancer. EuPA Open Proteom. 2015;8:104–15.

Hua W, Dijke P, Kostidis S, Giera M, Hornsveld M. TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cell Mol Life Sci. 2020;77:2103–23.PubMed

Ishikawa S, Nishida N, Fujino S, Ogino T, Takahashi H, Miyoshi N, et al. Comprehensive profiling of novel epithelial–mesenchymal transition mediators and their clinical significance in colorectal cancer. Sci Rep. 2021;11(1):1–16.

Sinha A, Dijke P. E3 Ubiquitin ligases: key regulators of TGFβ signaling in cancer progression. Int J Mol Sci. 2021;22:476.PubMedCentral

10.

Angioni R, Sánchez-Rodríguez R, Viola A, Molon B. TGF-β in Cancer: metabolic driver of the tolerogenic crosstalk in the tumor microenvironment. Cancers. 2021;13:401.PubMedPubMedCentral

11.

Ciardiello D, Elez E, Tabernero J, Seoane J. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. Ann Oncol. 2020;31:1336–49.

12.

Dardare J, Witz A, Merlin J-L, Gilson P, Harlé A. SMAD4 and the TGFβ pathway in patients with pancreatic ductal adenocarcinoma. Int J Mol Sci. 2020;21:3534.

13.

Wang J, Xiang H, Lu Y, Wu T. Role and clinical significance of TGF-β1 and TGF-βR1 in malignant tumors (Review). Int J Mol Med. 2021. https://doi.org/10.3892/ijmm.2021.4888.CrossRefPubMedPubMedCentral

14.

Jung H, Yoon S, Lim J, Cho HJ, Lee H. Dysregulation of Rho GTPases in Human Cancers. Cancers. 2020;12:1179.PubMedCentral

15.

Campbell H, Fleming N, Roth I, Mehta S, Wiles A, Williams G, et al. Δ133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signaling. Nat Commun. 2018. https://doi.org/10.1038/s41467-017-02408-0.CrossRefPubMedPubMedCentral

16.

Rodrigues P, Macaya I, Bazzocco S, Mazzolini R, Andretta E, Dopeso H, et al. Abstract 2058: RHOA inactivation enhances Wnt signaling and promotes colorectal cancer. Nat Commun. 2014;5:5458.PubMed

17.

Chen J, Ding Z-y, Li S, Liu S, Xiao C, Li Z, et al. Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy. Theranostics. 2021;11:1345–63.PubMedPubMedCentral

18.

Cammareri P, Vincent D, Hodder M, Ridgway R, Murgia C, Nobis M, et al. TGFβ pathway limits dedifferentiation following WNT and MAPK pathway activation to suppress intestinal tumourigenesis. Cell Death Differ. 2017;24:1681–93.PubMedPubMedCentral

19.

Vu T, Datta PK. Regulation of EMT in colorectal cancer: a culprit in metastasis. Cancers. 2017;9(12):171.PubMedCentral

20.

Zhang Z, Zheng S, Lin Y, Sun J, Ding N, Chen J, et al. Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients. BMC Cancer. 2020. https://doi.org/10.1186/s12885-020-07615-5.CrossRefPubMedPubMedCentral

21.

Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000;103(2):295–309.PubMed

22.

Tian F, Byfield SD, Parks WT, Yoo S, Felici A, Tang B, et al. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Can Res. 2003;63(23):8284–92.

23.

Xie W, Rimm D, Lin Y, Shih W, Reiss M. Loss of Smad Signaling in Human Colorectal Cancer Is Associated with Advanced Disease and Poor Prognosis. Cancer journal (Sudbury, Mass). 2003;9:302–12.

24.

Zhao G, Wojciechowski MC, Jee S, Boros J, McAvoy JW, Lovicu FJ. Negative regulation of TGFβ-induced lens epithelial to mesenchymal transition (EMT) by RTK antagonists. Exp Eye Res. 2015;132:9–16.PubMed

25.

Wang H, Liu S, Kong F, Xiao F, Li Y, Wang H, et al. Spred2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by impairing ERK signaling. Oncol Rep. 2020. https://doi.org/10.3892/or.2020.7586.CrossRefPubMedPubMedCentral

26.

Papageorgis P, Cheng K-H, Ozturk S, Gong Y, Lambert A, Mostafavi Abdolmaleky H, et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Can Res. 2011;71:998–1008.

27.

Samanta D, Datta P. Alterations in the Smad pathway in human cancers. Front Biosci. 2012;17:1281–93.

28.

Maitra A, Molberg K, Albores-Saavedra J, Lindberg G. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol. 2000;157:1105–11.PubMedPubMedCentral

29.

Inamoto S, Itatani Y, Yamamoto T, Minamiguchi S, Hirai H, Iwamoto M, et al. Loss of SMAD4 promotes colorectal cancer progression by accumulation of myeloid-derived suppressor cells through CCL15-CCR1 Chemokine Axis. Clin Cancer Res. 2015;22:492–501.PubMed

30.

Peyravian N, Nobili S, Pezeshkian Z, Olfatifar M, Moradi A, Baghaei K, et al. Increased Expression of VANGL1 is Predictive of Lymph Node metastasis in colorectal cancer: results from a 20-Gene expression signature. J Personalized Med. 2021;11(2):126.

31.

Seshimo I, Yamamoto H, Mishima H, Kurata A, Suzuki R, Ezumi K, et al. Expression and mutation of SMAD4 in poorly differentiated carcinoma and signet-ring cell carcinoma of the colorectum. J Exp Clin Cancer Res. 2006;25:433–42.PubMed

32.

Tsubakihara Y, Moustakas A. Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β. Int J Mol Sci. 2018;19:3672.PubMedCentral

33.

Hao Y, Baker D, Dijke P. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci. 2019;20:2767.PubMedCentral

34.

Itatani Y, Kawada K, Sakai Y. Transforming growth Factor-β signaling pathway in colorectal cancer and its tumor microenvironment. Int J Mol Sci. 2019;20:5822.PubMedCentral

35.

Pradhan R, Ngo P, Martínez-Sánchez L, Neurath M, López PR. Rho GTPases as key molecular players within intestinal mucosa and GI Diseases. Cells. 2021;10:66.PubMedCentral

36.

Dopeso H, Rodrigues P, Bilic J, Bazzocco S, Carton-Garcia F, Macaya I, et al. Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. British J Cancer. 2017;118:106–16.

37.

Nowrin K, Sohal S, Peterson G, Patel R, Walters E. Epithelial-mesenchymal transition as a fundamental underlying pathogenic process in COPD airways: Fibrosis, remodeling and cancer. Expert Rev Respir Med. 2014;8:1–13.

38.

Rice A, Cortes E, Lachowski D, Oertle P, Matellan C, Thorpe S, et al. GPER activation inhibits cancer cell mechanotransduction and basement membrane invasion via RhoA. Cancers. 2020;12:289.PubMedCentral

39.

Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin J-P, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res. 2005;11(7):2606–11.PubMed

40.

Kriegl L, Horst D, Reiche J, Engel J, Kirchner T, Jung A. LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J Transl Med. 2010;8:123.PubMedPubMedCentral

41.

Repetto L, Gianni W, Agliano A, Gazzaniga P. Impact of EGFR expression on colorectal cancer patient prognosis and survival: a response. Ann Oncol. 2005;16(9):1557.PubMed

42.

Huang K, Gao N, Bian D, Zhai Q, Yang P, Li M, et al. Correlation between FAK and EGF-induced EMT in colorectal cancer cells. J Oncol. 2020;2020:1–10.

43.

Li D-Q, Pakala S, Nair S, Eswaran J, Kumar R. Metastasis-Associated Protein 1/Nucleosome Remodeling and Histone Deacetylase Complex in Cancer. Can Res. 2012;72:387–94.

44.

Toh Y, Nicolson G. The role of the MTA family and their encoded proteins in human cancers: Molecular functions and clinical implications. Clin Exp Metas. 2009;26:215–27.

45.

Pakala SB, Singh K, Reddy SDN, Ohshiro K, Li D-Q, Mishra L, et al. TGF-β1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene. 2011;30(19):2230–41.PubMedPubMedCentral

46.

Zhu W, Cai M-Y, Tong Z-T, Dong S-S, Mai S-J, Liao Y-J, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial–mesenchymaltransition. Gut. 2012;61(4):562–75.PubMed

47.

Cagatay S, Cimen I, Savas B, Banerjee S. MTA-1 expression is associated with metastasis and epithelial to mesenchymal transition in colorectal cancer cells. Tumour Biol. 2013;34:1189–204.

48.

Li J, Ye L, Sun P-H, Satherley L, Hargest R, Zhang Z, et al. MTA1 Is Up-regulated in colorectal cancer and is inversely correlated with lymphatic metastasis. Cancer Genomics Proteomics. 2015;12:339–45.PubMed

Titel: A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways
verfasst von: Marzieh Shirin
Sajedeh Madadi
Noshad Peyravian
Zahra Pezeshkian
Leili Rejali
Masoumeh Hosseini
Afshin Moradi
Binazir Khanabadi
Ghazal Sherkat
Hamid Asadzadeh Aghdaei
Ehsan Nazemalhosseini-Mojarad
Publikationsdatum: 01.04.2022
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2022
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-021-01634-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

ErbB2 promotes breast cancer metastatic potential via HSF1/LDHA axis-mediated glycolysis

Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells

Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer

The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma

A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy

CDK9 inhibitors in multiple myeloma: a review of progress and perspectives

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie